Will a new drug form work the same? study tests two versions of SKI-O-703

NCT ID NCT07675226

Not yet recruiting Knowledge-focused Sponsor: Oscotec Inc. Source: ClinicalTrials.gov ↗

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This study tests whether two different capsule forms of the experimental drug SKI-O-703 are absorbed similarly in the body. About 48 healthy adults (Korean and Caucasian) will take a single dose of each form on separate days, with blood samples taken to compare drug levels. The results will help determine which form to use in future studies for conditions like immune thrombocytopenia and rheumatoid arthritis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SKI-O-703
What this could lead to: If the two forms are shown to be equivalent, this could simplify manufacturing and dosing for future trials in immune thrombocytopenia and rheumatoid arthritis.
What could go wrong: This is an early-phase study in healthy volunteers, not patients. The drug may not work as hoped in actual disease conditions, and side effects could emerge in later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIOEQUIVALENCE STUDY IN HEALTHY SUBJECTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Purpura, Thrombocytopenic, Idiopathic rheumatoid arthritis thrombocytopenia due to immune destruction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BIOEQUIVALENCE STUDY IN HEALTHY SUBJECTS IMMUNE THROMBOCYTOPENIA (ITP) RHEUMATOID ARTHRITIS (RA)

More trials for these conditions

Other studies related to the condition(s) this trial covers.